Research Paper Volume 12, Issue 24 pp 25275—25293

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

class="figure-viewer-img"

Figure 4. Construction of the recurrence methylation model for patients with LUAD. (A) Kaplan-Meier curves of the recurrence model of patients in the high- and low-risk groups. (B) Accuracy of the prognostic model in predicting recurrence rate by time-dependent ROC curve analysis. LUAD, lung adenocarcinoma; ROC, receiver operating characteristic.